Search research articles
Contact Us
Filters
Showing results (191-200 of 273) with videos related to
Page
of 28
Sort By:
The Oncologist
|
December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis
Steven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Blood Advances
|
March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
Reid W Merryman, Natasha Edwin, Robert Redd, et al.
Blood Advances
|
April 3, 2019
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease
Roger Belizaire, Haesook T Kim, Samuel J Poryanda, et al.
British Journal of Haematology
|
June 26, 2013
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma
Philippe Armand, Yasuhiro Oki, Donna S Neuberg, et al.
Leukemia & Lymphoma
|
August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation
Eleanor Taranto, Robert Redd, Erin Jeter, et al.
Blood Advances
|
May 7, 2020
BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
Eduardo Espada, Matthew P Cheng, Haesook T Kim, et al.
Bone Marrow Transplantation
|
October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation
Zachariah DeFilipp, Shuli Li, David Avigan, et al.
Blood
|
September 6, 2024
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
Katie Maurer, Isabella N Grabski, Roch Houot, et al.
Blood Advances
|
August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Stephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Page
of 28
Search research articles
Search
Showing results (191-200 of 273) with videos related to
Sort By:
Page
of 28
The Oncologist
|
December 21, 2018
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis
Steven M Bair, Lauren E Strelec, Tatyana A Feldman, et al.
Blood Advances
|
March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma
Reid W Merryman, Natasha Edwin, Robert Redd, et al.
Blood Advances
|
April 3, 2019
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease
Roger Belizaire, Haesook T Kim, Samuel J Poryanda, et al.
British Journal of Haematology
|
June 26, 2013
Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma
Philippe Armand, Yasuhiro Oki, Donna S Neuberg, et al.
Leukemia & Lymphoma
|
August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation
Eleanor Taranto, Robert Redd, Erin Jeter, et al.
Blood Advances
|
May 7, 2020
BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
Eduardo Espada, Matthew P Cheng, Haesook T Kim, et al.
Bone Marrow Transplantation
|
October 17, 2019
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation
Zachariah DeFilipp, Shuli Li, David Avigan, et al.
Blood
|
September 6, 2024
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
Katie Maurer, Isabella N Grabski, Roch Houot, et al.
Blood Advances
|
August 2, 2023
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
Stephen M Ansell, Paul J Bröckelmann, Gottfried von Keudell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Page
of 28